Mortality risk factors of Acinetobacter baumannii bacteraemia
- PMID: 16207259
- DOI: 10.1111/j.1445-5994.2005.00925.x
Mortality risk factors of Acinetobacter baumannii bacteraemia
Abstract
Background: Acinetobacter baumannii is one of the most important nosocomial pathogens, and its multiple antibiotic resistance has emerged as an obstacle in the treatment of these infections worldwide.
Aims: To identify risk factors of mortality for A. baumannii bacteraemia.
Methods: A retrospective cohort study of 72 patients with significant A. baumannii bacteraemia was conducted to evaluate risk factors for mortality.
Results: The median age of the 72 enrolled patients was 48 years, 96% of the cases were hospital-acquired, and the bacteraemia-related mortality rate was 29% (21 of 72 patients). Univariate analysis revealed that the risk factors for mortality included: an elevated acute physiology and chronic health evaluation (APACHE II) score, receipt of in vitro ineffective definitive antimicrobial therapy, in vitro A. baumannii resistance to cefoperazone/ sulbactam, neutropenia, and presentation with septic shock. Multivariate analysis reveals that the independent risk factors for mortality are neutropenia and elevated APACHE II scores.
Conclusion: Risk factors such as neutropenia and elevated APACHE II scores are found to be associated with higher mortality rates of A. baumannii bacteraemia. Further study is necessary for the determination of optimal strategies for both the prevention and treatment of these infections.
Similar articles
-
The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes.J Hosp Infect. 2006 Nov;64(3):282-7. doi: 10.1016/j.jhin.2006.06.025. Epub 2006 Aug 22. J Hosp Infect. 2006. PMID: 16930770
-
Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.Eur J Intern Med. 2009 Sep;20(5):540-4. doi: 10.1016/j.ejim.2009.05.005. Epub 2009 May 29. Eur J Intern Med. 2009. PMID: 19712862
-
Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.Int J Antimicrob Agents. 2007 Nov;30(5):409-14. doi: 10.1016/j.ijantimicag.2007.06.026. Epub 2007 Sep 11. Int J Antimicrob Agents. 2007. PMID: 17851052
-
Therapeutic options for Acinetobacter baumannii infections.Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587. Expert Opin Pharmacother. 2008. PMID: 18312160 Review.
-
Acinetobacter baumannii skin and soft-tissue infection associated with war trauma.Clin Infect Dis. 2008 Aug 15;47(4):444-9. doi: 10.1086/590568. Clin Infect Dis. 2008. PMID: 18611157 Review.
Cited by
-
Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.Medicine (Baltimore). 2016 Mar;95(9):e2943. doi: 10.1097/MD.0000000000002943. Medicine (Baltimore). 2016. PMID: 26945403 Free PMC article.
-
No evidence for a common blood microbiome based on a population study of 9,770 healthy humans.Nat Microbiol. 2023 May;8(5):973-985. doi: 10.1038/s41564-023-01350-w. Epub 2023 Mar 30. Nat Microbiol. 2023. PMID: 36997797 Free PMC article.
-
Lipocalin-2 is an essential component of the innate immune response to Acinetobacter baumannii infection.PLoS Pathog. 2022 Sep 2;18(9):e1010809. doi: 10.1371/journal.ppat.1010809. eCollection 2022 Sep. PLoS Pathog. 2022. PMID: 36054235 Free PMC article.
-
Mapping Global Prevalence of Acinetobacter baumannii and Recent Vaccine Development to Tackle It.Vaccines (Basel). 2021 Jun 1;9(6):570. doi: 10.3390/vaccines9060570. Vaccines (Basel). 2021. PMID: 34205838 Free PMC article. Review.
-
Impact of empirical antimicrobial therapy on the outcome of critically ill patients with Acinetobacter bacteremia.Ann Thorac Med. 2015 Oct-Dec;10(4):256-62. doi: 10.4103/1817-1737.164302. Ann Thorac Med. 2015. PMID: 26664563 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
